Literature DB >> 30527441

New ex vivo model of corneal endothelial phacoemulsification injury and rescue therapy with mesenchymal stromal cell secretome.

Majid Rouhbakhshzaeri1, Behnam Rabiee1, Nathalie Azar1, Elham Ghahari1, Ilham Putra1, Medi Eslani1, Ali R Djalilian2.   

Abstract

PURPOSE: To develop a reproducible ex vivo model of corneal endothelial cell injury using phacoemulsification in porcine eyes and to evaluate the effects of mesenchymal stromal cell secretome in this injury model.
SETTING: Department of Ophthalmology, University of Illinois at Chicago, Illinois, USA.
DESIGN: Experimental study.
METHODS: A corneal endothelial injury model was optimized using different powers and durations of ultrasound energy inside ex vivo porcine eyes. Conditioned media from corneal mesenchymal stem cells was collected under serum-free conditions from passages 4 to 6. Immediately after the phacoemulsification injury, the anterior chamber fluid was replaced with unconditioned media or conditioned media and incubated at 37°C for 4 hours. At the end, endothelial cell viability was evaluated using trypan blue staining and analyzed with ImageJ software.
RESULTS: Using specific parameters (50% power for 30 seconds), phacoemulsification inside fresh porcine eyes led to a consistent level of endothelial cell injury. Incubation with corneal mesenchymal stromal cell-conditioned media after the injury significantly reduced endothelial cells loss compared with unconditioned media (mean 1.29% ± 0.91% [SD] and 5.33% ± 3.24%, respectively, P < .05).
CONCLUSIONS: Phacoemulsification inside fresh porcine eyes provided a reproducible model to study endothelial cell injury. Treatment with corneal mesenchymal stromal cell secretome after injury appeared to significantly enhance the survival of corneal endothelial cells. This might provide a new strategy for preventing corneal endothelial cell loss after phacoemulsification or other endothelial injuries. Further in vivo studies are necessary to determine the therapeutic potential.
Copyright © 2018 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30527441      PMCID: PMC6409103          DOI: 10.1016/j.jcrs.2018.09.030

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  44 in total

1.  Endothelial cell integrity after phacoemulsification with 2 different handpieces.

Authors:  Luis G Vargas; Mike P Holzer; Kerry D Solomon; Helga P Sandoval; Gerd U Auffarth; David J Apple
Journal:  J Cataract Refract Surg       Date:  2004-02       Impact factor: 3.351

2.  Risk factors for corneal endothelial injury during phacoemulsification.

Authors:  K Hayashi; H Hayashi; F Nakao; F Hayashi
Journal:  J Cataract Refract Surg       Date:  1996-10       Impact factor: 3.351

3.  Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury.

Authors:  Joo Youn Oh; Gavin W Roddy; Hosoon Choi; Ryang Hwa Lee; Joni H Ylöstalo; Robert H Rosa; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

4.  Corneal endothelial cell loss after pars plana vitrectomy and combined phacoemulsification-vitrectomy surgeries.

Authors:  Keyvan Koushan; Mikel Mikhail; Anne Beattie; Nina Ahuja; Allan Liszauer; Lawrence Kobetz; Forough Farrokhyar; James A Martin
Journal:  Can J Ophthalmol       Date:  2016-10-01       Impact factor: 1.882

5.  Initial clinical evaluation of an intraocular femtosecond laser in cataract surgery.

Authors:  Zoltan Nagy; Agnes Takacs; Tamas Filkorn; Melvin Sarayba
Journal:  J Refract Surg       Date:  2009-12       Impact factor: 3.573

6.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.

Authors:  Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

7.  TSG-6 protects corneal endothelium from transcorneal cryoinjury in rabbits.

Authors:  Jeong-Ah Kim; Jung Hwa Ko; Ah Young Ko; Hyun Ju Lee; Mee Kum Kim; Won Ryang Wee; Ryang Hwa Lee; Samuel F Fulcher; Joo Youn Oh
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-17       Impact factor: 4.799

8.  Therapy of corneal endothelial dysfunction with corneal endothelial cell-like cells derived from skin-derived precursors.

Authors:  Lin Shen; Peng Sun; Canwei Zhang; Le Yang; Liqun Du; Xinyi Wu
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

9.  Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage.

Authors:  Sang Jin Kim; Jung Hwa Ko; Ji-Hyun Yun; Ju-A Kim; Tae Eun Kim; Hyun Ju Lee; Seok Hwan Kim; Ki Ho Park; Joo Youn Oh
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Neda Afsharkhamseh; Soroush Besharat; Mark I Rosenblatt; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

View more
  2 in total

Review 1.  Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy.

Authors:  Rebecca M Harman; Charlotte Marx; Gerlinde R Van de Walle
Journal:  Front Cell Dev Biol       Date:  2021-03-19

2.  Lysophosphatidic acid improves corneal endothelial density in tissue culture by stimulating stromal secretion of interleukin-1β.

Authors:  Yi-Jen Hsueh; Yaa-Jyuhn James Meir; Jui-Yang Lai; Hung-Chi Chen; David Hui-Kang Ma; Chieh-Cheng Huang; Tsai-Te Lu; Chao-Min Cheng; Wei-Chi Wu
Journal:  J Cell Mol Med       Date:  2020-04-24       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.